Abstract 147P
Background
In 2017, the 8th edition of the Union for International Cancer Control TNM classification (TNM8) was published and clinical staging system was newly defined. Recently, this clinical staging reportedly predicted the prognosis in patients with gastric cancer (GC). Different from common GC, the diagnosis and the treatment of adenocarcinoma of the esophagogastric junction (AEG) have been controversial. Moreover, its incidence also has increased in Japan. The purpose of this study was to clarify whether the prognosis of patients with Siewert type II/III tumors was appropriately stratified by the clinical staging system.
Methods
Patients who were diagnosed with AEG type II/III and received gastrectomy or esophagectomy between 1986 and 2014 at Kanagawa Cancer Center were included in this study. Patients received neoadjuvant chemotherapy were excluded.
Results
A total of 196 patients were examined, 123 (63%) patients had type II tumor and 73 (37%) had type III. 41 patients were classified to clinical stage I, 40 were to stage II, 104 were to stage III, and 11 were to stage IV, respectively. The median follow-up period of the survivors was 58.3 months. The 5-year overall survival rate was 48.8 % in whole cohort and were 82.5% in stage I, 70.0% in stage II, 31.7% in stage III, and 9.1% in stage IV. The hazard ratio to stage I was 1.93 in stage II, 5.68 in stage III, and 11.8 in stage IV, which increased in a stepwise manner with the stage.
Conclusions
The clinical staging system of TNM8 could appropriately stratify the prognosis of the patients with Siewert type II/III tumors.
Clinical trial identification
This study was approved by the institutional review board of Kanagawa Cancer Center. (Epidemiological Study-23).
Editorial acknowledgement
Legal entity responsible for the study
Kanagawa Cancer Center.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session